DOR BioPharma awarded $500,000 for clinical study

PRINCETON, N.J. -- The National Institutes of Health (NIH) has awarded DOR BioPharma a $500,000 Small Business Innovation Research grant to support a clinical evlauation of DOR201, a time-release formulation of oral BDP for the prevention of acute radiation enteritis.

The study will evaluate the safety and maximal tolerated dose of DOR201, and its efficacy in preventing symptoms of acute radiation enteritis.

Acute radiation enteritis results from the radiation-induced death of cells in the lining of the bowel. Gastrointestinal toxicity develops from an inflammatory response to dead cells and bacteria, manifesting itself in chronic diarrhea, vomiting and pain.

"Radiation enteritis is a serious complication for colorectal cancer patients receiving radiation therapy that impacts their quality of life and can require treatment modification," stated William Small, Jr., MD, a principal investigator for the clinical study. "Based on oral BDP's proven pharmacology in treating severe gastrointestinal inflammation, DOR201 represents a potential prophylactic option that would enable physicians/patients to maintain planned treatment regimens to battle the underlying malignancy.”

Organizations in this Story

National Institutes of Health

Want to get notified whenever we write about National Institutes of Health ?
Next time we write about National Institutes of Health, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.